Otsuka Holdings Raises FY2026 Earnings Forecast 34% on Drug Strength
Otsuka Holdings Co., Ltd. (TSE:4578) has raised its full-year earnings and dividend guidance for the fiscal year ending December 2026, citing robust performance in its pharmaceutical division and delayed generic competition.
| Item | Before | After | Change |
|---|---|---|---|
| 売上収益 | JPY 2520.0bn | JPY 2725.0bn | +8.1% |
| 事業利益 | JPY 355.0bn | JPY 470.0bn | +32.4% |
| Operating Profit | JPY 360.0bn | JPY 469.0bn | +30.3% |
| 税引前当期利益 | JPY 353.0bn | JPY 472.0bn | +33.7% |
| 当期利益 | JPY 269.0bn | JPY 360.0bn | +33.8% |
| 親会社の所有者に帰属する当期利益 | JPY 265.0bn | JPY 355.0bn | +34.0% |
| 基本的１株当たり当期利益 | JPY 505M | JPY 675M | +33.8% |
The company attributed the upward revision to stronger-than-expected first-half results in its pharmaceutical business, driven by growth in key products including antipsychotic Lexapro, anticancer agent Lonsurf, and anti-APRIL antibody Voyxact. Additionally, delayed generic entry for U.S. Zyprexa and European Abilify Maintena has bolstered pharmaceutical revenue projections to JPY 1934.0bn, an upward adjustment of JPY 195.0bn. The nutraceutical division’s Healthier Life category also performed well. Currency headwinds were partially offset by yen weakness assumptions revised to 158 yen per dollar and 185 yen per euro from prior estimates.
The company raised its annual dividend per share by 42.9% to JPY 200.00/share, with interim and year-end payouts each set at JPY 100.00/share under its progressive dividend policy. The earnings beat and enhanced shareholder returns underscore management confidence in pharmaceutical pipeline momentum and operational execution through year-end 2026.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.